Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The clinical success of inhibitors of tumour necrosis factor (TNF) in the treatment of autoimmune diseases has generated interest in the therapeutic potential of targeting other members of the TNF superfamily (TNFSF) of cytokines and their receptors. Here, Croft and colleagues review the current developmental status of biologics targeting these molecules in a range of disorders, highlighting key challenges and emerging therapeutic targets.
The accumulation of eosinophils in blood and tissue is associated with several inflammatory and infectious diseases. Here, the authors describe recent advances in the development of first-generation eosinophil-targeted therapies and highlight innovative new strategies — such as inhibiting eosinophil activation — that are aimed at targeting eosinophils.
